These observations indicated that POL, ACT, and FTB were beneficial in reducing pulmonary inflammation through suppressing NF-κB activation and blocking IκBα degradation, leading to suppression of proinflammatory gene programs and lower expression of IL-1β, IL-6, and IL-8. The gene discussed is CXCL8; the disease is inflammatory response.